PMID: 11918513Mar 29, 2002Paper

Treatment of resistant depression by adding noradrenergic agents to lithium augmentation of SSRIs

The Annals of Pharmacotherapy
Rajamannar Ramasubbu

Abstract

To examine the efficacy of second-line augmentation with noradrenergic antidepressants (NAs) in depressed patients who partially responded to lithium augmentation of selective serotonin-reuptake inhibitors (SSRIs). Six patients with major depression or double depression (major depression and dysthymia) who were partially responsive to lithium and SSRI treatment were given either bupropion or desipramine, in an open clinical manner. Improvement was determined and rated by a psychiatrist based on clinical judgment guided by the Clinical Global Impression (CGI) improvement scale and by the Global Assessment of Functioning (GAF) as described in Axis V in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Among the 6 depressed patients with partial remission (much improved in symptoms and moderate functional improvement: CGI score 2, GAF score 51-60) while taking the SSRI and lithium combination, 2 showed complete remission (very much improved in symptoms and good functioning: CGI 1, GAF 80-100) and 3 achieved near-complete remission (very much improved in symptoms and significant functional recovery: CGI 1, GAF 61-80) when given either bupropion or desipramine. One patient did not show any additional clinica...Continue Reading

References

Oct 1, 1992·The British Journal of Psychiatry : the Journal of Mental Science·R SethK Bergmann
Nov 1, 1986·The American Journal of Psychiatry·L H PriceG R Heninger
Jan 1, 1983·Progress in Neuro-psychopharmacology & Biological Psychiatry·R H BelmakerE Dick
Apr 1, 1981·Occupational Health Nursing·J Himmelhoch
Oct 1, 1995·The American Journal of Psychiatry·J C Nelson, L H Price
Apr 1, 1995·Biological Psychiatry·U HalbreichK Wang
Mar 1, 1993·Clinical Pharmacokinetics·J van Harten
Apr 1, 1997·The Journal of Clinical Psychiatry·J A BodkinR J Baldessarini
Apr 1, 1997·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·A DubiniV Polin
Jul 1, 1997·Archives of General Psychiatry·R S DumanE J Nestler
Feb 24, 1998·Journal of Clinical Psychopharmacology·B D Lebowitz, M V Rudorfer
Apr 30, 1999·The Journal of Clinical Psychiatry·R B Ostroff, J C Nelson
Nov 24, 1999·Biological Psychiatry·K J Ressler, C B Nemeroff
Mar 25, 2000·The Journal of Clinical Psychiatry·S M Stahl

❮ Previous
Next ❯

Citations

Oct 1, 2006·Acta Neuropsychiatrica·Robert D Goldney, Marcus A Bain
Oct 4, 2008·Journal of Psychiatric Practice·Andrew F LeuchterJonathan W Stewart
Nov 19, 2004·Social Psychiatry and Psychiatric Epidemiology·Robert D Goldney, Laura J Fisher
Aug 24, 2007·Expert Opinion on Investigational Drugs·Russell T Joffe
Mar 17, 2007·The Psychiatric Clinics of North America·Andrew A NierenbergMaurizio Fava
Jan 22, 2010·CNS Drugs·Richard C SheltonSara A Corya
Dec 18, 2019·The Cochrane Database of Systematic Reviews·Philippa DaviesNicola Wiles

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.